603567.SH
珍宝岛
SSE · Healthcare · Drug Manufacturers - Specialty & Generic · CN
CNY 5.32
−5.67%Income statement
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Revenue | |||||
| Total Revenue | 510.4M | 798.1M | 2.7B | 3.1B | 4.2B |
| Cost of Revenue | 882.8M | 820.1M | 1.2B | 1.8B | 3.5B |
| Gross Profit | (372.3M) | (22.1M) | 1.5B | 1.3B | 744.8M |
| Operating Expenses | |||||
| R&D Expense | 51.6M | 46.3M | 38.0M | 80.2M | 70.9M |
| SG&A Expense | — | — | — | — | — |
| General & Admin Expense | 220.7M | 231.8M | 304.4M | 333.7M | 322.0M |
| Selling & Marketing Expense | 98.8M | 132.9M | 291.6M | 668.2M | 608.3M |
| Other Expenses | — | — | — | — | — |
| Total Operating Expenses | 502.9M | 549.1M | 811.1M | 1.3B | 1.2B |
| Cost and Expenses | 1.4B | 1.4B | 2.0B | 3.1B | 4.7B |
| Operating Income (EBIT) | (1.9B) | (1.6B) | 523.3M | 473.2M | 297.5M |
| Non-Operating | |||||
| Interest Income | 492.3K | 727.9K | 2.6M | 5.3M | 5.3M |
| Interest Expense | — | — | — | — | — |
| Net Interest Income | — | — | — | — | — |
| Other Non-Op Income/Expense | — | — | — | — | — |
| Non-Operating Income (excl Interest) | — | — | — | — | — |
| EBT (Pre-Tax Income) | (1.9B) | (1.6B) | 523.5M | 478.3M | 298.5M |
| Income Tax Expense | (315.8M) | (257.5M) | 87.1M | 10.8M | 107.6M |
| Bottom Line | |||||
| Net Income | (1.6B) | (1.4B) | 438.2M | 472.7M | 185.4M |
| Earnings from Cont. Ops | (1.6B) | (1.4B) | 436.4M | 467.6M | 190.9M |
| Earnings from Discont. Ops | — | — | — | — | — |
| Bottom Line Net Income | (1.6B) | (1.4B) | 438.2M | 472.7M | 185.4M |
| Per Share | |||||
| Basic EPS | (CN¥1.73) | (CN¥1.45) | CN¥0.47 | CN¥0.50 | CN¥0.20 |
| Diluted EPS | (CN¥1.73) | (CN¥1.45) | CN¥0.47 | CN¥0.50 | CN¥0.20 |
| Revenue Per Share | CN¥0.54 | CN¥0.85 | CN¥2.88 | CN¥3.35 | CN¥4.48 |
| Shares | |||||
| Basic Shares Outstanding | 941.6M | 939.8M | 940.0M | 939.5M | 941.3M |
| Diluted Shares Outstanding | 941.6M | 939.8M | 940.0M | 939.5M | 941.3M |
| Profitability Metrics | |||||
| EBITDA | — | (1.4B) | 669.6M | 662.8M | 466.7M |
| D&A | — | 184.4M | 146.4M | 189.6M | 169.1M |
| EBIT | — | — | — | — | — |
As reported, in the filing currency · TTM sums the four latest quarters; MRQ is the latest quarter · Negatives in parentheses; a dash is a line the filing does not carry · Data as of Mar 1, 2026